1. Home
  2. CIA vs ADAG Comparison

CIA vs ADAG Comparison

Compare CIA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens Inc. ($1.00 Par)

CIA

Citizens Inc. ($1.00 Par)

HOLD

Current Price

$5.23

Market Cap

264.9M

Sector

Finance

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.58

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIA
ADAG
Founded
1969
2011
Country
United States
China
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.9M
254.4M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CIA
ADAG
Price
$5.23
$3.58
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
67.1K
151.8K
Earning Date
05-07-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$255,616,000.00
N/A
Revenue This Year
$3.10
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$28.23
N/A
Revenue Growth
4.33
N/A
52 Week Low
$3.25
$1.44
52 Week High
$6.40
$4.75

Technical Indicators

Market Signals
Indicator
CIA
ADAG
Relative Strength Index (RSI) 48.01 45.25
Support Level $5.09 $3.40
Resistance Level $5.59 $3.99
Average True Range (ATR) 0.26 0.28
MACD -0.04 -0.01
Stochastic Oscillator 35.03 54.48

Price Performance

Historical Comparison
CIA
ADAG

About CIA Citizens Inc. ($1.00 Par)

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: